AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00565669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A Restasis®
Study NCT00565669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blink tears
Description: blink tears to be used twice a day
Study NCT00565669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane
Description: systane to be used twice a day
Study NCT03598582 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin Zeta
Description: Patients received epoetin zeta (Retacrit®) 40000UI/week subcutaneously during 12 weeks.~Response has been evaluated at 12 weeks according to IWG 2006 criteria. Patients with response continued on epoetin zeta. In non-responders, the patients have been excluded from the protocol.
Study NCT02272933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart Slipper
Description: The shoe measures foot pressure and motion allowing gait to be quantified.
Study NCT02272933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belt-Clip Sensor
Description: The sensor measures acceleration of the body allowing falls to be detected.
Study NCT03723421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Injection Group Without Aspiration
Description: After filling in the personal information form, the tetanus vaccine was administered by using rapid injection without aspiration technique (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). (the injector was held at 90 degrees, it was pricked into tissue rapidly, and the drug was given in 1-2 seconds without performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
Study NCT03723421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: After filling in the personal information form, the tetanus vaccine was made in accordance with the standard injection technique included in the application (the injector was held at 90 degrees, it was pricked into tissue, and the drug was given in 5-10 seconds after performing aspiration). 2 days after the vaccination, the researcher got in contact with the students in the intervention and the control groups in order to ask whether a local side effect developed in the vaccination site or not.
Study NCT02552498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: strangulation
Description: The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
Study NCT03315611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 'Eucerin AtopiControl Lotion' (for the body)
Description: Treatment with Eucerin AtopiControl Lotion
Study NCT03315611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen challenge chamber
Description: Exposure to Dactylis glomerata pollen in an environmental challenge chamber
Study NCT03315611 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen challenge chamber
Description: Exposure to Dactylis glomerata pollen in an environmental challenge chamber
Study NCT03684421 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy Rate
Description: The clinical pregnancy and live birth rate according to the protocol of COS
Study NCT06504888 — intervention group
Intervention type: DRUG
Intervention: Penicillin
Description: Compare whether there is a higher incidence of sinus elevation in patients allergic to penicillin compared to non-allergic patients, evaluating clinical histories.
Study NCT04110717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestal Device
Description: Vestibular nerve stimulator
Study NCT04110717 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control Device
Description: Control Device
Study NCT04110717 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypocaloric Diet
Description: Hypocaloric diet
Study NCT04110717 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Hypocaloric Diet
Description: Hypocaloric diet
Study NCT03266575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation Exercise
Description: Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
Study NCT03266575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Based Exercise
Description: Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
Study NCT01861418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbopelvic Manipulation
Description: Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
Study NCT01861418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham manipulation
Description: Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
Study NCT03927677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanthine Oxidase Inhibitor
Description: LC350189 200mg qd
Study NCT04454710 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Radiofrequency
Description: Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.
Study NCT04454710 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsed Radiofrequency
Description: Pulsed radiofrequency is a novel therapeutic modality with many potential applications in pain management.
Study NCT00904839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: BIBF 1120 100 and 150 mg capsules
Study NCT00904839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBF 1120
Description: BIBF 1120 100 and 150 mg capsules
Study NCT00904839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFolfox
Description: standard i.v chemotherapy
Study NCT00904839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 100 mg/Kg solution , IV infusion
Study NCT00904839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFolfox 6
Description: IV standard chemotherapy
Study NCT00904839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 100 mg/4 ml solution
Study NCT00833118 — intervention group
Intervention type: PROCEDURE
Intervention: Jaw thrust maneuver (Intubation)
Description: Visualization of Larygnoscopic anatomy during intubation
Study NCT01832818 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NuNec Cervical Disc
Description: Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
Study NCT00796614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: Oral
Study NCT05315154 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No axillary surgery
Description: In the study arm will be omitted surgery in axilla
Study NCT05315154 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SLNB
Description: in the control arm will be realized SLNB
Study NCT04016246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol-Lipuro
Description: sedation of babies \< 32wGA with propofol / placebo before a LISA Procedure
Study NCT04016246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: injected to babies \< 32wGA with propofol / placebo before a LISA Procedure
Study NCT02920814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Description: Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
Study NCT02612610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant administered as one 7.5 mg, 20 mg, or 50 mg tablet twice daily, depending upon randomization.
Study NCT02612610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for gefapixant)
Study NCT00554541 — intervention group
Intervention type: OTHER
Intervention: Ankle Brachial Index Venous physiologic study
Description: Assessment of lower extremity venous disease
Study NCT00796614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT00049335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, on Days 1-14 of 21 day cycle
Study NCT03955354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study NCT03955354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib mesylate
Description: apatinib Mesylate is a small molecule tyrosine kinase inhibitor,Through selectively inhibiting the tyrosine kinase activity of the vascular endothelial growth factor receptor 2 (VEGFR-2).
Study NCT02946307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restore DEB（dimeter>2.00 mm）
Study NCT02946307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute DES
Study NCT02946307 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Restore DEB（dimeter:2.00 mm）
Study NCT02580968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
Study NCT02580968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flunarizine hydrochloride
Description: flunarizine hydrochloride ，10mg/day，for 20 days。
Study NCT02073721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrostimulation with exercises MAPs
Description: this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
Study NCT02073721 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises MAPs
Description: This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
Study NCT04316520 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Ketogenic diet 2:1
Study NCT03511378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupin's Pegfilgrastim
Description: Administration of Pegfilgrastim
Study NCT03511378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neulasta®
Description: Administration of Neulasta®
Study NCT01101464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 3x5mg followed by 1x15mg
Description: Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
Study NCT01101464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 1x15mg followed by 3x5mg
Description: One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
Study NCT04103086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Free aromatherapy (70% menthol and 30% propanediol) will be provided for 6 months. All participants will receive the standard inhalation method training before hospital discharge.~The aromatherapy will be given twice daily, one treatment in the morning and one in the evening. At each treatment, 4 deep steady inhalations will be performed, and 10 seconds per inhalation is optimal.
Study NCT04103086 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Free placebo (10% menthol and 90% propanediol) will be provided for 6 months. The specific method is the same as aromatherapy
Study NCT02652390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 80 mg
Description: 2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
Study NCT02652390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 mg
Description: 1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
Study NCT02652390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 2 mL saline + 1 mL lidocaine
Study NCT03867552 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Altered gas (86% CO2, 10% N2O, 4% O2)
Description: Assessment of pain degree after laparoscopic surgery with the altered gas (86% CO2, 10% N2O, 4% O2)
Study NCT03867552 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized gas (100% CO2)
Description: Assessement of pain degree after laparoscopic surgery with the standardized gas (100% CO2)
Study NCT00560313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Men ACWY CRM
Description: A single dose of a 0.5 mL injectable solution
Study NCT00560313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4CMenB
Description: All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
Study NCT01231464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate nasal spray
Description: fluticasone furoate nasal spray 110ug, once daily
Study NCT01231464 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00344253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta
Study NCT00344253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Study NCT03449134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
Study NCT03449134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
Study NCT03449134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 15 mg or 45 mg tablet administered orally BID during the 12-week main study period and during the 40-week extension period, according to randomization.
Study NCT01410084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 100,000 IU vitamin D3 once monthly for 5 months
Study NCT01410084 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E
Description: 400 IU vitamin E once monthly for 5 months
Study NCT00993798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine Treatment 1a
Description: 5.0 ml
Study NCT00993798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SABER-Bupivacaine Treatment 1b
Description: 5.0 ml
Study NCT00993798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Treatment 1c
Description: 20.0 ml
Study NCT00993798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine Treatment 2a
Description: 7.5 ml
Study NCT00993798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SABER-Bupivacaine Treatment 2b
Description: 7.5 ml
Study NCT00993798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl Treatment 2c
Description: 20.0 ml
Study NCT00383630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of bone marrow mononuclear cells
Description: 6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
Study NCT00383630 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of CD34+ selected bone marrow mononuclear cells
Description: 6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
Study NCT00383630 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: LVAD alone
Description: LVAD implantation without any intramyocardial injection of bone marrow cells.
Study NCT00887198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: 1000 mg per day (4 x 250-mg tablets) taken orally.
Study NCT03027206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibration technique
Description: Comparison of different technique
Study NCT03027206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceleration of expiratory flow
Description: Comparison of different technique
Study NCT03422159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic Acid 1.5g IV piggyback every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Study NCT03422159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: Thiamine 200mg IV piggyback every 12 hours for 4 days (or discharge from ICU if prior to 4 days).
Study NCT03422159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone 50mg IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Study NCT03422159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Placebo Ascorbic Acid 100mL IV piggyback every 6 hours, Placebo Thiamine 50mL IV piggyback every 12 hours, and Placebo Hydrocortisone IV push every 6 hours for 4 days (or discharge from ICU if prior to 4 days).
Study NCT01744171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine
Description: Given ID
Study NCT01744171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00003045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
Study NCT00003045 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT
Description: external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
Study NCT03872258 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Counseling on physical activity
Study NCT03872258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Counseling on physical activity
Study NCT03872258 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Program of combined exercise and a Smartband for 6 months.
Study NCT00829829 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
Study NCT00829829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept 80 mg
Description: Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
Study NCT00829829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept 160 mg
Description: Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.